30.45 USD
↗ 0.73 (2.46%)AT CLOSE (11:59 AM EDT)
NewAmsterdam Pharma Company N.V. Ordinary Shares
NAMSNASDAQ • USD
30.50
↗ 0.05 (0.15%)
POST MARKET (AS OF 05:44 PM EDT)
Post Market
AS OF 05:44 PM EDT
30.50
↗ 0.05 (0.15%)
Market: CLOSED
Open?$30.78
High?$31.32
Low?$29.84
Prev. Close?$29.72
Volume?1.3M
Avg. Volume?878.5K
VWAP?$30.18
Rel. Volume?1.45x
Bid / Ask
Bid?$29.50 × 100
Ask?$35.21 × 300
Spread?$5.71
Midpoint?$32.36
Valuation & Ratios
Market Cap?3.5B
Shares Out?116.9M
Float?56.9M
Float %?50.5%
P/E Ratio?N/A
P/B Ratio?5.12
EPS?-$1.77
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?7.86Strong
Quick Ratio?7.86Strong
Cash Ratio?5.71Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUED
Score58/100
P/E?N/A▾
P/B?5.12FAIR▾
P/S?155.58HIGH▾
P/FCF?N/A▾
EV/EBITDA?-13.4CHEAP▾
EV/Sales?133.80HIGH▾
Returns & Efficiency
ROE?-29.8%WEAK▾
ROA?-26.5%WEAK▾
Cash Flow & Enterprise
FCF?$-148029000
Enterprise Value?$3.0B
Fundamentals ratios updated end of day
xxx
Related Companies
Loading...
News
Profile
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
Employees
100
Market Cap
3.4B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2022-11-23
Address
GOOIMEER 2-35
NARRDEN, P7 1411 DC
Phone: 35 206 2971
NARRDEN, P7 1411 DC
Phone: 35 206 2971